Discover
CLDX
Celldex Therapeutics, Inc.
39.12
1 x 33.28
1 x 45.91
bid
ask
-
0.51
1.29%
12:37 PM
timesize
| Ytd | 44.04% | |
| 1y | 77.17% |
39.01
day range
39.90
22.06
52 week range
44.87
| Open | 39.13 | Prev Close | 39.63 | Low | 39.01 | High | 39.90 | Mkt Cap | 3.07B |
| Vol | 153.07K | Avg Vol | 1.03M | EPS | -4.35 | P/E | N/A | Forward P/E | -9.52 |
| Beta | 0.87 | Short Ratio | 7.85 | Inst. Own | 110.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 38.54 | 200-d Avg | 31.27 | 1yr Est | 58.07 |
| Income Statement | |||
| Total Revenue | 22.00K | ||
| Revenues (USD) | 22.00K | ||
| Gross Profit | 22.00K | ||
| Operating Expenses | 80.65M | ||
| Research and Development Expense | 67.54M | ||
| Selling, General and Administrative Expense | 13.10M | ||
| Operating Income | -80.62M | ||
| Net Income | -73.50M | ||
| Net Income Common Stock | -73.50M | ||
| Net Income Common Stock (USD) | -73.50M | ||
| Consolidated Income | -73.50M | ||
| Earnings per Basic Share | -0.94 | ||
| Earnings per Basic Share (USD) | -0.94 | ||
| Earnings per Diluted Share | -0.94 | ||
| Earning Before Interest & Taxes (EBIT) | -73.50M | ||
| Earning Before Interest & Taxes (USD) | -73.50M | ||
| Weighted Average Shares | 77.84M | ||
| Weighted Average Shares Diluted | 77.84M | ||
| Balance Sheet | |||
| Cash and Equivalents | 47.45M | ||
| Cash and Equivalents (USD) | 47.45M | ||
| Investments | 670.13M | ||
| Investments Current | 670.13M | ||
| Trade and Non-Trade Receivables | 230.00K | ||
| Current Assets | 724.93M | ||
| Property, Plant & Equipment Net | 14.79M | ||
| Total Assets | 782.35M | ||
| Debt Current | 1.56M | ||
| Total Debt | 4.90M | ||
| Current Liabilities | 61.33M | ||
| Debt Non-Current | 3.35M | ||
| Total Liabilities | 67.79M | ||
| Accumulated Retained Earnings (Deficit) | -1.97B | ||
| Accumulated Other Comprehensive Income | 1.30M | ||
| Shareholders Equity | 714.56M | ||
| Shareholders Equity (USD) | 714.56M | ||
| Assets Non-Current | 57.42M | ||
| Total Debt (USD) | 4.90M | ||
| Goodwill and Intangible Assets | 27.19M | ||
| Liabilities Non-Current | 6.46M | ||
| Trade and Non-Trade Payables | 14.68M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 902.00K | ||
| Net Cash Flow from Financing | 324.66M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 11.73M | ||
| Capital Expenditure | -3.18M | ||
| Issuance (Purchase) of Equity Shares | 324.66M | ||
| Net Cash Flow from Investing | -255.52M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -252.34M | ||
| Net Cash Flow from Operations | -57.41M | ||
| Share Based Compensation | 8.41M | ||